High-dose alfacalcidol improves anaemia in patients on haemodialysis | Zendy

S. Albitar | Zendy; R Genin | Zendy; M. Fen-Chong | Zendy; M. O. Serveaux | Zendy; D. Schohn | Zendy; C. Chuet | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

High-dose alfacalcidol improves anaemia in patients on haemodialysis

Author(s) -

S. Albitar,

R Genin,

M. Fen-Chong,

M. O. Serveaux,

D. Schohn,

C. Chuet

Publication year - 1997

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/12.3.514

Subject(s) - alfacalcidol , medicine , hyperparathyroidism , secondary hyperparathyroidism , endocrinology , gastroenterology , vitamin d and neurology , urology , surgery , parathyroid hormone , calcium , bone mineral , osteoporosis

Alfacalcidol is efficient for treating secondary hyperparathyroidism in patients on maintenance haemodialysis (HD). Little is known about the direct impact of high-dose alfacalcidol on anaemia in end-stage renal failure. We therefore carried out a prospective study over 18 months to examine the direct effect of high-dose alfacalcidol on erythropoiesis in erythropoietin (rHuEpo)-dependent anaemic patients on HD for more than 6 months with moderate hyperparathyroidism.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research